﻿<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Cision News</title><link>https://news.cision.com</link><description>Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations.</description><pubDate>Tue, 09 Jun 2026 09:13:54 GMT</pubDate><image><title>Cision News</title><width>146</width><height>60</height><link>https://news.cision.com</link><url>https://news.cision.com/Content/img/news-logo.png</url></image><item><title>Nutra Pharma Provides Sales and Marketing Update</title><link>http://news.cision.com/nutra-pharma-corporation/r/nutra-pharma-provides-sales-and-marketing-update,c9352203</link><guid isPermaLink="false">cision1206298</guid><description><![CDATA[Nutra Pharma is providing an update on the sales and marketing efforts of TCN as they begin their global marketing campaign for Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin™.
Coral Springs, FL. – December 20, 2012 - Nutra Pharma Corp. (OTCQB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is providing updates on the sales and marketing activities of TCN, a distributor of Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin™ (http://www.nyloxin.net/).

In September 2012, Nutra Pharma]]></description><pubDate>Thu, 20 Dec 2012 19:11:02 GMT</pubDate></item><item><title>Nutra Pharma Introduces Nyloxin™ Military Strength</title><link>http://news.cision.com/nutra-pharma-corporation/r/nutra-pharma-introduces-nyloxin--military-strength,c9350866</link><guid isPermaLink="false">cision1204876</guid><description><![CDATA[Nutra Pharma is introducing a stronger version of its over-the-counter (OTC) pain reliever, Nyloxin™, and has begun the process of registration with the United States government for sales into the military.
Coral Springs, FL. – December 19, 2012 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be introducing a stronger version of its over-the-counter (OTC) pain reliever, Nyloxin™ (http://www.nyloxin.net/). The new product will be called Nyloxin™ Military]]></description><pubDate>Wed, 19 Dec 2012 14:00:00 GMT</pubDate></item><item><title>Nutra Pharma Letter to Shareholders</title><link>http://news.cision.com/nutra-pharma-corporation/r/nutra-pharma-letter-to-shareholders,c9350864</link><guid isPermaLink="false">cision1203868</guid><description><![CDATA[Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company
December 18, 2012 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the Company's Chief Executive Officer, Rik J Deitsch, had published a Shareholder Letter on the Company's website.

“We have been very busy here at Nutra Pharma,” explained Rik J Deitsch,]]></description><pubDate>Tue, 18 Dec 2012 14:32:14 GMT</pubDate></item><item><title>Nutra Pharma Begins Marketing Nyloxin™ Through Direct Distributors</title><link>http://news.cision.com/nutra-pharma-corporation/r/nutra-pharma-begins-marketing-nyloxin--through-direct-distributors,c9308382</link><guid isPermaLink="false">cision1121478</guid><description><![CDATA[Nutra Pharma announces the direct distribution of their Nyloxin™ line of pain relievers through TCN, a network of distributors in more than 20 countries.
September 20, 2012 -- Coral Springs, Florida -- Nutra Pharma Corporation (Pink Sheets: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have begun selling Nyloxin through the TCN group of direct distributors.

“We are excited to be working with TCN to aggressively market and sell Nyloxin,” explained]]></description><pubDate>Fri, 21 Sep 2012 16:10:22 GMT</pubDate></item><item><title>Nutra Pharma Begins Affiliate Sales &amp; Marketing Program for the Distribution of Nyloxin™</title><link>http://news.cision.com/nutra-pharma-corporation/r/nutra-pharma-begins-affiliate-sales---marketing-program-for-the-distribution-of-nyloxin-,c9254016</link><guid isPermaLink="false">cision488144</guid><description><![CDATA[Nutra Pharma announces the roll-out of a two-level, on-line affiliate sales and marketing plan for the sales and distribution of their Nyloxin™ line of pain relievers.
May 2, 2012 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that LWR Partners, their outside branding and marketing firm, has begun their on-line affiliate sales and marketing program to aid in the promotion, branding and distribution]]></description><pubDate>Wed, 02 May 2012 13:00:00 GMT</pubDate></item></channel></rss>